553 related articles for article (PubMed ID: 31549358)
1. Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.
Galaj E; Xi ZX
CNS Drugs; 2019 Oct; 33(10):1001-1030. PubMed ID: 31549358
[TBL] [Abstract][Full Text] [Related]
2. Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge.
Soler-Cedeno O; Xi ZX
Cells; 2022 Oct; 11(20):. PubMed ID: 36291128
[TBL] [Abstract][Full Text] [Related]
3. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.
Tai S; Vasiljevik T; Sherwood AM; Eddington S; Wilson CD; Prisinzano TE; Fantegrossi WE
Drug Alcohol Depend; 2018 Nov; 192():285-293. PubMed ID: 30300803
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.
Sholler DJ; Huestis MA; Amendolara B; Vandrey R; Cooper ZD
Pharmacol Biochem Behav; 2020 Dec; 199():173059. PubMed ID: 33086126
[TBL] [Abstract][Full Text] [Related]
5. Xie2-64, a novel CB
Jordan CJ; Feng ZW; Galaj E; Bi GH; Xue Y; Liang Y; McGuire T; Xie XQ; Xi ZX
Neuropharmacology; 2020 Oct; 176():108241. PubMed ID: 32712273
[TBL] [Abstract][Full Text] [Related]
6. Modern approaches to the development of synthetic cannabinoid receptor probes.
Saldaña-Shumaker SL; Grenning AJ; Cunningham CW
Pharmacol Biochem Behav; 2021 Apr; 203():173119. PubMed ID: 33508249
[TBL] [Abstract][Full Text] [Related]
7. Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.
Aly E; Masocha W
IBRO Neurosci Rep; 2021 Jun; 10():109-118. PubMed ID: 34179865
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates.
Kangas BD; Zakarian AS; Vemuri K; Alapafuja SO; Jiang S; Nikas SP; Makriyannis A; Bergman J
J Pharmacol Exp Ther; 2020 Jan; 372(1):119-127. PubMed ID: 31641018
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
Tai S; Nikas SP; Shukla VG; Vemuri K; Makriyannis A; Järbe TU
Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse.
Vasiljevik T; Franks LN; Ford BM; Douglas JT; Prather PL; Fantegrossi WE; Prisinzano TE
J Med Chem; 2013 Jun; 56(11):4537-50. PubMed ID: 23631463
[TBL] [Abstract][Full Text] [Related]
11. New approaches in the design and development of cannabinoid receptor ligands: multifunctional and bivalent compounds.
Nimczick M; Decker M
ChemMedChem; 2015 May; 10(5):773-86. PubMed ID: 25820617
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid CB
He XH; Jordan CJ; Vemuri K; Bi GH; Zhan J; Gardner EL; Makriyannis A; Wang YL; Xi ZX
Acta Pharmacol Sin; 2019 Mar; 40(3):365-373. PubMed ID: 29967454
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists.
Kangas BD; Delatte MS; Vemuri VK; Thakur GA; Nikas SP; Subramanian KV; Shukla VG; Makriyannis A; Bergman J
J Pharmacol Exp Ther; 2013 Mar; 344(3):561-7. PubMed ID: 23287700
[TBL] [Abstract][Full Text] [Related]
14. The endocannabinoid system as a target for addiction treatment: Trials and tribulations.
Sloan ME; Gowin JL; Ramchandani VA; Hurd YL; Le Foll B
Neuropharmacology; 2017 Sep; 124():73-83. PubMed ID: 28564576
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
Davis MP
Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
[TBL] [Abstract][Full Text] [Related]
17. Contrasting effects of different cannabinoid receptor ligands on mouse ingestive behaviour.
Grey J; Terry P; Higgs S
Behav Pharmacol; 2012 Sep; 23(5-6):551-9. PubMed ID: 22772336
[TBL] [Abstract][Full Text] [Related]
18. Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development.
Nguyen T; Thomas BF; Zhang Y
Curr Top Med Chem; 2019; 19(16):1418-1435. PubMed ID: 31284863
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of cannabinoid ligand-induced modulations in intracellular Ca
Xia KK; Shen JX; Huang ZB; Song HM; Gao M; Chen DJ; Zhang SJ; Wu J
Acta Pharmacol Sin; 2019 Mar; 40(3):410-417. PubMed ID: 30202013
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice.
Schlosburg JE; Carlson BL; Ramesh D; Abdullah RA; Long JZ; Cravatt BF; Lichtman AH
AAPS J; 2009 Jun; 11(2):342-52. PubMed ID: 19430909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
